A case study to learn more about the challenge of running clinical studies during pandemic lockdowns
OM Pharma wanted to assess the feasibility of running clinical trials of a treatment to prevent respiratory tract infections (RTIs) during the Covid-19 lockdown.
Nova built a multi-scale in silico model capturing how non-pharmaceutical interventions (NPI) – such as lockdown or mask-wearing – affect rates of infection with the most common respiratory viruses, and the impact of the prophylactic treatment OM-85 under different NPI scenarios in the context of an upcoming trial.
How nova approached the challenge
Download case study
Get your questions answered by downloading the free pdf and learn more about our study!